BRD4 PROTAC Degrader With Modular Linker Architecture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective methods to target and degrade cMET proteins, which are implicated in various diseases, particularly cancer, using PROTAC compounds.
Innovation Solution
A novel PROTAC compound is developed, comprising a cMET protein-binding moiety and an E3 ligase-binding moiety linked by a linker, which induces the degradation of cMET proteins through polyubiquitination and proteasome degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PROTAC compound is designed to bind to cMET protein and E3 ligase simultaneously, then protein degradation capability is improved, but device complexity increases
Solution Approach 1:
The PROTAC compound is segmented into three functional modules: a cMET-binding ligand portion, an E3 ligase-binding ligand portion, and a linker portion connecting them. This segmentation allows each module to independently perform its function while maintaining overall molecular stability, resolving the contradiction between degradation capability and structural complexity.
Solution Approach 2:
The PROTAC compound serves multiple functions simultaneously: it acts as a molecular glue to bring cMET and E3 ligase together, serves as a scaffold for polyubiquitination, and triggers proteasomal degradation. This multi-functionality within a single molecule improves degradation capability without proportionally increasing complexity.
2Reliability
If linker length is increased to improve binding flexibility, then binding affinity is improved, but molecular stability deteriorates
Solution Approach 1:
The linker length is optimized to specific values (e.g., 6-12 atoms) to achieve the optimal balance between flexibility for binding and stability for molecular integrity. This parameter optimization resolves the contradiction by finding the precise value where both binding affinity and molecular stability are maximized.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTAC compound effectively binds to and degrades cMET proteins, offering therapeutic potential for cMET-related diseases, including cancer, with demonstrated anticancer effects.
Implementation Method 1
PROTAC binds to both proteins simultaneously, bringing the target protein very close to E3 ligase, which recognizes the target protein as a substrate and triggers polyubiquitination and subsequent proteasome degradation
Data Source
Figure 1
AI summary
A TPD compound is disclosed. The present invention relates to a PROTAC compound that binds to the BRD4 protein, and since it can bind to the BRD4 protein and degrade it, it can be useful for the treatment or prevention of diseases related to the BRD4 protein. The compound of the present invention has an excellent anticancer effect, and can also induce the degradation of BRD4 protein, which can show a therapeutic effect on BRD4 and related diseases.